Characteristics of data holding
| Metastatic | Early-stage | ||
|---|---|---|---|
| Trastuzumab | Lapatinib | Trastuzumab | |
| Dispensing records, total (N) | 1 100 594 | 261 496 | 1 763 268 |
| Dispensing records, HER2-targeted therapy (N) | 145 907 | 8000 | 171 605 |
| Medical services records (N) | 2 221 760 | 536 370 | – |
| Type of medical service, overall, claims, N (%) | |||
| Pathology | 897 597 (40.4) | 225 210 (42.0) | – |
| Attendances/consults/visits | 599 277 (27.0) | 135 521 (25.3) | – |
| Specialist | 329 077 (14.8) | 79 266 (14.8) | – |
| General practitioner | 236 649 (10.7) | 48 614 (9.1) | – |
| Enhanced primary care | 13 045 (0.6) | 3095 (0.6) | – |
| Practice nurse | 8264 (0.4) | 2100 (0.4) | – |
| Other | 12 242 (0.6) | 2446 (0.5) | – |
| Diagnostic imaging | 199 411 (9.0) | 48 081 (9.0) | – |
| Radiotherapy/nuclear medicine | 136 490 (6.1) | 36 276 (6.8) | – |
| Miscellaneous (eg, medical supplies) | 388 985 (17.5) | 91 282 (17.0) | – |
HER2, human epidermal growth factor receptor 2.